"Drug Repositioning" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The deliberate and methodical practice of finding new applications for existing drugs.
| Descriptor ID |
D058492
|
| MeSH Number(s) |
E05.295.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Repositioning".
Below are MeSH descriptors whose meaning is more specific than "Drug Repositioning".
This graph shows the total number of publications written about "Drug Repositioning" by people in this website by year, and whether "Drug Repositioning" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Repositioning" by people in Profiles.
-
Moore E, Reynolds JA, Davidson A, Gallucci S, Morel L, Rao DA, Young HA, Putterman C. Promise and complexity of lupus mouse models. Nat Immunol. 2021 06; 22(6):683-686.
-
Chen A, Patel S, Alcusky M, Maio V. Will the COVID-19 Pandemic Finally Fuel Drug Repurposing Efforts? Am J Med Qual. 2021 Mar-Apr 01; 36(2):122-124.
-
Sun S, Su W, Lin CQ, Li X, Yan H, Tian B, Lin H. COVID-19: the novel coronavirus disease and its manifestations and management in ophthalmology. Discov Med. 2020 May-Jun; 29(158):145-157.
-
Pederson T. Snatched from oblivion: "second lives" of bespoke drugs. FASEB J. 2020 01; 34(1):1-2.
-
Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Meyskens FL, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019 01 01; 125(1):18-44.
-
Lohinai Z, Dome P, Szilagyi Z, Ostoros G, Moldvay J, Hegedus B, Dome B, Weiss GJ. From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC). PLoS One. 2016; 11(1):e0144797.